info@strategicmarketresearch.com
26, Broadway, Suite 934, New York , 10004
us US: +1-315-636-4233    uk UK: +44-162-237-0614     in IN: +91-826-083-6500
smrlogonew
  • Home
  • About
    • Why SMR
    • Research Methodology
    • Media Coverage
    • Join Our Team
  • Reports
    • Aerospace and Defense
    • Agriculture
    • Automotive
    • Chemicals and Materials
    • Consumer Goods
    • Energy and Power
    • Equipment and Machinery
    • Food and Beverages
    • Healthcare
    • Information and Communication Technology
    • Semiconductor and Electronics
    • Manufacturing and Construction
  • Our Practices
    • Syndicated Research
    • Consulting Services
    • Custom Research
    • Full-time Engagement Model
  • Insights
    • Press Release
    • Blog
  • Contact
 
Home » Healthcare » Recombinant DNA Technology Market Size, Industry Forecast

Recombinant DNA Technology Market By Product (Therapeutic Agent, Vaccine, Genetically Modified Crops, Speciality Chemicals), By Component (Expression System, Cloning Vector), By Application (Food and Agriculture, Environment, Health, Disease Fighting), By End-User (Academic & Government Research Institutes, Biotechnological and Pharmaceutical Companies, Others), By Geography, Size, Global Growth Analysis, Industry Forecast, 2021-2030

Published On: Jul-2022   |   Base Year: 2021   |   No Of Pages: 140   |   Historical Data: 2017 - 2020   |   Formats: PDF   |   Report ID: 47243480

Industry Report and Statistics (Facts & Figures) - Demand & Sales by Product Type, Application & Components

The global recombinant DNA technology market will witness a robust CAGR of 7.7%, valued at $707.20 billion in 2021, expected to appreciate and reach $1378.76 billion by 2030, confirms Strategic Market Research. Recombinant DNA Technology (rDNA technology) uses enzymes and technology to split or combine a single or multiple genes as required and introduce them into a new organism to achieve a new, desired characteristic. The application of the technology finds itself in fields of agriculture, human therapeutics, vaccine manufacture, poultry industry, high-yield farm animals, and forensics, few among others. The technology uses various types of cells, strata, and media for its application. Two of the most common types of cells used in recombinant DNA technology are yeast cells and bacterial cells. The bacterial cells are used because they contain DNA material outside the chromosomes called a plasmid. This makes the genetic material easier to access for users in rDNA technology. Similarly, yeast cells are also used in the technology as they have active proteins, which are easier to integrate into newer cells.  When the genetic material is transferred to a new cell, it is done by using restriction enzymes, which help in providing a site in the host cell.

With a wide application range of this technology, we see that the recombinant DNA technology industry has a high market value and many competitors. For example, the United States administered Recombinant Influenza Vaccine, which was introduced to protect against the seasonal influenza virus. As of the 2021-22 season, the USA had distributed over 174 million doses. The vaccine is produced using recombinant DNA technology. CDC has estimated that there were nearly 7.4 to 12 million flu illnesses in the 2021-22 season; hence, the vaccines made it possible to reduce the number of deaths caused by flu in the given year.

 

Recombinant DNA Technology Infographic with Overall Segment Estimation 2020-2030

 

Key Industry Drivers - Investments in R&D, Producing Transgenic Animals, Genetically Modified Crops, Vaccines

  • rDNA technology has been used increasingly in the global scenario having various positive outcomes, and companies are investing heavily in the sector. The Malaghan Institute of Medical Research, based in Wellington, New Zealand, announced in May 2022 that it would invest USD 40 million over the next 4 years in developing vaccines as a part of its development program. As a whole, with technology advancing at a rapid pace, there will be further investment in the sector that will accelerate the industry's growth.

 

  • Poultry, livestock, and pisciculture industries have benefited from using rDNA technology due to the improved yield of the products of the respective industries. The AquAdavantage salmon is an example of a transgenic fish developed by the company AquaBounty Technology by using the growth hormone from the Chinook variety of salmon to reduce the time period in which they grow. The dairy industry also makes use of the developments; for example, the recombinant bovine somatotropin (rBST) hormone greatly improved the health of dairy and beef cattle, improving the output of the industry, which in turn is expediting the recombinant DNA technology market analysis. In a study conducted by Fesseha et al. (2020) showed that, on average, the use of rBST increased the total output by 14.7% per day.

 

  • Genetically modified crops have been grown since the mid-1990s.The first ever commercially genetically modified (GM) crop was the ‘Flavr Savr’ tomato developed by Calgene, an American genetic engineering company. Following this, companies developed other GM crops, namely - soybean, cotton, and corn, which are widely used. As of 2020, according to the US Department of Agriculture (USDA), over 90% of the land used for growing corn and soybean is through genetically modified seeds to be resistant to pests and weeds. With climate change and more resistant forms of pests and weeds, there would be a need to produce more advanced GM crops.

 

  • Vaccines are used to prevent major diseases, and the first vaccine approved using recombinant DNA technology was the hepatitis B virus (HBV) vaccine. Another commonly used rDNA vaccine is the HPV vaccine. Using the recombinant DNA technology, there were several companies and institutes, such as Karolinska Institute in collaboration with Cobra Biologics, amongst others, that developed rDNA vaccines.  According to the CDC, over 1 billion vaccine doses, including Covid, were given in the year 2021. Therefore, there is huge potential to develop vaccines using recombinant DNA technology, thereby augmenting its industry growth.

 

Restraints

The restraint for a company in the industry is the time consumed in developing new products, which also implies a high investment in the sector. At times, there are objections from the public towards using GM products.

 

Opportunities - CRISPR, Therapeutic Applications, Gene Therapy

  • Clustered regularly interspaced short palindromic repeats or widely known as CRISPR is a method by which prokaryotes defend themselves against viruses. The discovery of the CRISPR genome editing method was named “Breakthrough of the Year” by Science Magazine in 2015. In the year 2018, the U.S. FDA approved a clinical trial for using the CRISPR/Cas mode of gene editing as a therapy for people having a gene mutation causing blindness at birth. The widespread and undiscovered application of this technology presents itself as a tremendous opportunity for recombinant DNA technology.

 

  • There are several trials underway for the use of recombinant DNA technology for human applications. The diseases in focus are cancer and AIDS. Eli Lilly, an American pharmaceutical company, produced Humulin - artificial insulin to aid in the condition of diabetes, using recombinant DNA technology. According to the CDC, over 37 million Americans have diabetes, and 20% of the cases are undiagnosed.  According to the CDC, there are over 48 million human papillomaviruses (HPV) infections. The vaccine was developed in 1990 and helped reduce the number of active infections significantly. With the discovery of insulin and the HPV vaccine using recombinant DNA technology, there is huge scope for the discovery and application of more human enzymes and cures for diseases.

 

  • Gene therapy is a method used to modify and /or manipulate gene expression to treat or cure a disease. An FDA-approved drug for type 1 spinal muscular atrophy, ZOLGENSMA, was developed by Novartis and approved for use in October 2021. The development of gene therapies aids in enhancing or reducing gene expressions to control and prevent diseases. Thus, we can see that further research in gene therapy would enhance a company’s opportunity in the market to treat complicated diseases.

 

Recombinant DNA Technology Market Analysis Of Different Segments Covered in the Report

Based on Product:

  • Therapeutic Agent

  • Vaccine

  • Genetically Modified Crops

  • Specialty Chemicals

 

Based on Component:

  • Expression System

  • Cloning Vector

 

Based on Application

  • Food and Agriculture

  • Environment

  • Health

  • Disease Fighting

 

Based on End User

  • Academic & Government Research Institutes

  • Biotechnological and Pharmaceutical Companies

  • Others

 

Regional Coverage Analysis

North America

  • USA

  • Canada

  • Mexico

 

Europe

  • Germany

  • United Kingdom

  • France

  • Italy

  • Spain

  • Rest of Europe

 

Asia-Pacific

  • Australia

  • China

  • India

  • Japan

  • South Korea

 

The Middle East and Africa

  • GCC

  • South Africa

  • Rest of the Middle East and Africa

 

South America

  • Argentina

  • Brazil

  • Rest of South America

 

global recombinant dna technology market share forecast 2020 2030

 

Segments Analysis & Insights

Going by the product segmentation, The Therapeutic agent segment led the recombinant DNA technology market growth in all aspects in 2020. Therapeutic agents are those which are used for the treatment of an ailment or disease. Several therapeutic agents have been FDA approved and used for various diseases and conditions. For example, the FDA approved EPOGEN, which was erythropoietin alfa in 2007 and has been used to treat anemia caused by renal failure and HIV infection cancers.

The recombinant DNA technology in plants has helped produce genetically modified crops. According to the USDA, in 2013, approximately half of the land to grow crops was used for growing genetically modified crops. Further, according to the USDA, on average, fruit and nut crops generate USD 25 billion in cash receipts in the farming industry. In 2017, Okanagan Speciality fruits developed a GM fruit, specifically a GM apple named ‘Arctic Apple’ with the feature of non-browning when exposed to oxygen. Therefore, further development of GM crops and therapeutic agents would increase the revenue sources for companies in the market.

 

Going by application, the health and disease diagnostics segments would be at par with the food and agriculture segments due to the wide range of applications in each sector. Follicle-stimulating hormone (FSH) is an important hormone useful in sexual development and the sexual health cycle. FDA had approved artificial FSH, which is developed using recombinant DNA technology by Ferring Pharmaceuticals. It is sold under the brand name Bravelle. According to the CDC, among women aged from 15 to 49 with no prior birth history, 19% (1 out of 5) are unable to get pregnant after one year of trying. Therefore, medications like Bravelle are extremely helpful. Interferon is a naturally occurring group of proteins that help fight viruses. However, due to various medical conditions, the body may not be able to produce interferon. In such cases, it is necessary to inject artificially produced interferon. Interferon, developed by two companies, namely Hoffman-La Roche Inc. and Schering-Plough Corporation, was the first to get approval for interferon alfa by the FDA in 1986. Following this, other companies also began R&D and received approvals for other forms of interferon. Ampicillin is an example of a drug created using recombinant DNA technology. It treats various throat, neck, lung, GI infections, and other infections such as meningitis.

In the food industry, lysozyme is a critical enzyme that is used to preserve foods. It prevents the growth of microorganisms that are prone to spoil food. According to the FDA, more than 95% of all animals reared for dairy and meat consume feed that is made from GM crops. The increase in dairy cattle's milk yield is due to bovine somatotropin use. FDA approved the use of the hormone, which is sold under the brand name Polisac.

 

Going by region, North America holds the highest industry share at 52.3%. This is because of the high number of pharmaceutical and biotechnological companies and research institutes in the region. In 2021, Fujifilm Diosynth Biotechnologies invested USD 2 billion in facility expansion. As asserted by the US Bureau of Economic Analysis, the biotechnology sector accounted for nearly 1.5% of the US economy's total GDP. With policies and infrastructure in place that favor the setting up of businesses in the region, it makes for an attractive destination for investment in the market.

 

Recombinant DNA Technology Market Report Coverage

Report Attribute

Details

Forecast Period

2021 - 2030

The market size value in 2021

USD 707.20 billion

The revenue forecast in 2030

USD 1378.76 billion

Growth rate

CAGR of 7.7 %

The base year for estimation

2021

Historical data

2017 – 2020

Unit

USD Billion, CAGR (2021 - 2030)

Segmentation

By Product, Component, Application, End User, and Region.

By Product

Therapeutic Agent, Vaccine, Genetically Modified Crops, Speciality Chemicals

By Application

Food and Agriculture, Environment, Health, and Disease Fighting

By End-User

Biotechnology and Pharmaceutical Industries, Academic and Research Institutes, Others

By Region

North America, Europe, Asia-Pacific, and LAMEA

Country Scope

USA, South Korea, India, Brazil, and South Africa

Company Usability Profiles

Monsanto, Thermo Fisher Scientific Inc., Sanofi, Biogen, Novartis AG, Novo Nordisk, GenScript, Pfizer,  BASF, Bayer, DuPont Pioneer, Amgen

 

Recombinant DNA Technology Market Competitive Landscape Analysis

The market is highly attractive for investments and attracts many companies to it. The major players in the industry are:

  • Monsanto

  • Thermo Fisher Scientific Inc.

  • Sanofi

  • Biogen

  • Novartis AG

  • Novo Nordisk

  • GenScript

  • Pfizer

  • BASF

  • Bayer

  • DuPont Pioneer

  • Amgen

 

recombinant dna technology market regional coverage 2020 2030

 

Recent Developments

  • In June 2022, Samsung Bioepis announced SB12, which is a proposed biosimilar to Soliris (eculizumab), which aids in the treatment of paroxysmal nocturnal hemoglobinuria (PNH).  Soliris is a humanized monoclonal (IgG2/4), created in an NS0 cell line using recombinant DNA technology, which is used to treat PNH & hemolytic uremic syndrome in both adults & children (aHUS).

 

  • In May 2022, the European Medicines Agency approved the use of Xenpozyme (olipudase alfa) for the treatment of Niemann - Pick disease, which is a rare genetic disorder affecting the body’s ability to metabolize fat. It was developed by Sanofi using recombinant DNA technology.

 

  • On April 2022, the U.S. Food & Drug Administration (FDA) approved the commercial licensing of Novartis' multi-product, Recombinant DNA technology-driven gene therapy manufacturing facility in Durham. This authorization enabled the cutting-edge, 170,000-square-foot facility to manufacture, test, and commercially market Zolgensma and gene therapy products for ongoing and upcoming clinical trials.

 

  • On Jan 2022, Thermo Fisher Scientific successfully bought the Recombinant DNA technology-based protein Maker Company Prepro Tech worth USD 1.85 Billion. The NJ (New Jersey) based Prepro Tech adequately provides cytokines & its related products that are used widely in fermentation-based production of drugs and in cell culture. Now, it has become a part of Thermo Scientific’s business, where it will contribute to cell culture offerings and bioprocessing.

 

  • In December 2021, CORBEVAX was approved by the worldwide governments for emergency use as a vaccine against COVID-19. It was developed using recombinant DNA technology. Corbevax, a "recombinant protein sub-unit" vaccine, is made from a specific SARS-CoV-2 virus portion, the spike protein that may be seen on the virus's surface. The spike protein enables the virus to enter cells, where it may proliferate and transmit the disease. Since the body will already be prepared for an immune response when a real virus tries to invade, it is unlikely that the virus will cause significant harm to the body.

 

  • In November 2021, American medicine and vaccine producer Zoetis, a subsidiary of Pfizer, developed and distributed COVID-19 vaccines meant for animals and livestock. The technology used was subunit recombinant DNA technology. The advantage of manufacturing COVID-19 vaccines with Recombinant DNA technology leads to their improved efficacy and greater response predictability compared to the other vaccines.

 

Products that the Industry Leaders are Manufacturing

Name

Feature

Key Player

  Humulin

Controls Blood Sugar Levels.

Lilly Pharma

  Humatrope

Aids in people with SHOX deficiency aids growth for those with Turner’s Syndrome and aids growth in idiopathic short stature.

Lilly Pharma

  GoldenRice

Vitamin A enhanced rice.

Monsanto / Bayer

AquAdvantage

The reduced growth period for salmon.

AquaBounty Tech

 

Frequently Asked Question About This Report

The major players in the market are Monsanto, Thermo Fisher Scientific Inc., Sanofi, Biogen, Novartis AG, Novo Nordisk, GenScript, Pfizer, BASF, Bayer, DuPont Pioneer, Amgen

Recombinant DNA Technology or RDT for short, is the use of enzymes, laboratory techniques and processes to bring about changes in the DNA of species and introducing it to a separate species to get a desired output of the resultant combination of genes.

The market size for the recombinant DNA technology in 2020 was USD 656.34 billion.

The global Recombinant DNA Technology Market size was $707.20 billion in 2021 and is predicted to reach $1378.76 billion by 2030 with a CAGR of 7.7%.

The various uses of recombinant DNA are production of hormones, insulin and proteins for humans and insect resistant, high yield crops and gene therapy for various diseases.

The popular technology is in developing genetically modified plants, crops and animals

The key trends for the market are enhanced use of gene therapy, applications in the energy sector through producing biofuels such as bioethanol and biohydrogen as well as rapid development of use of therapeutic treatments over new drug developments.

The CAGR for the time period was 7.7%.

Three uses of recombinant DNA technology are: - In producing artificial proteins and hormones for medical conditions. - Producing genetically modified crops with higher yield and insect resistance. - Developing genetically modified animals for higher output and disease resistance.

The global Recombinant DNA Technology Market is expected to grow at a compound annual growth rate (CAGR) of 7.7% from 2021 to 2030 to reach USD $1378.76 billion by 2030.


Sources

https://www.ers.usda.gov/data-products/adoption-of-genetically-engineered-crops-in-the-u-s/recent-trends-in-ge-adoption/

https://www.cdc.gov/vaccines/covid-19/retail-pharmacy-program/index.html

https://www.ers.usda.gov/publications/pub-details/?pubid=45182

https://www.fda.gov/consumers/consumer-updates/fda-ensures-your-foods-animals-are-safe

 

 

 

 

1.   Introduction

       1.1. Study Objective

       1.2. Market Definition        

       1.3. Study Scope

              1.3.1. Markets Covered

              1.3.2. Geographic Scope

              1.3.3. Years Considered

              1.3.4. Stakeholders

2.   Research Methodology

       2.1. Data Procurement

       2.2. Paid Database

              2.2.1. Secondary Data

                     2.2.1.1. Key Secondary sources

              2.2.2. Primary Data

                     2.2.2.1 Primary sources

                     2.2.2.2. Key industry insights

                     2.2.2.3. Primary interviews with experts

                     2.2.2.4. Key primary respondent list

       2.3. Market Size Estimation

       2.4. Bottom-Up and Top-Down Approaches

              2.4.1.     Bottom-Up Approach

                     2.4.1.1.         Approach for arriving at market size by bottom-up analysis

              2.4.2.     Top-Down Approach

                     2.4.2.1.         Approach for Capturing Market Size by Top-Down Analysis

       2.5. Market Breakdown and Data Triangulation

       2.6. Research Methodology

       2.7. Risk Assessment

3.  Executive Summary

       3.1 Recombinant DNA Technology Market: Post-Covid-19

              3.1.1      Actual Scenario

              3.1.2      Pessimistic Scenario

              3.1.3      Optimistic Scenario

              3.1.4      Market Summary

4. Industry Outlook

       4.1 Market Snapshot

       4.2 Recombinant DNA Technology Market

              4.2.1      market, 2021 – 2028 (USD Million)

       4.3 Regional Business Analysis

              4.3.1      market, by region, 2021 - 2030 (USD Million)

       4.4 By Product Business Analysis

              4.4.1      market, By Product, 2021 - 2030 (USD Million)

       4.5 By Application Business Analysis

              4.5.1      market, By Application, 2021 - 2030 (USD Million)

       4.6 Component Business Analysis

              4.6.1      market, By Component, 2021 - 2030 (USD Million)

       4.7 End-User Business Analysis

              4.7.1      market, By End-User, 2021 - 2030 (USD Million)

       4.8 Value Chain Analysis

       4.9 Market Variable Analysis

              4.9.1      Market Drivers Analysis

              4.9.2      Market Restraints Analysis

       4.10 Business Environment Analysis Tool

              4.10.1      market PEST analysis

              4.10.2      market Porter’s analysis

       4.11 Penetration & Growth Prospect Mapping

5. Market Dynamics

       5.1. Introduction

       5.2. Market Dynamics

              5.2.1.     Drivers

              5.2.2.     Restraints

              5.2.3.     Opportunities

              5.2.4.     Challenges

       5.3. Impact of Covid-19 On Market

       5.4. Value Chain Analysis

       5.5. Ecosystem

       5.6. Patent Analysis

       5.7. Trade Analysis

       5.8. Tariff Analysis

       5.9. Case Study Analysis

5.10.      Porter’s Five Forces Analysis

              5.10.1    Threat of New Entrants

              5.10.2    Threat of Substitutes

              5.10.3    Bargaining Power of Buyers

              5.10.4    Bargaining Power of Suppliers

              5.10.5    Degree of Competition

       5.11.              End-User Analysis

              5.11.1.   Trends in End-User (2014-2021)

              5.11.2.   Trends in End-User (2021-2028)

       5.12.              Pricing Analysis

              5.12.1.   Average Price Trend Analysis (By Region, By Country)

6. Competitive & Vendor Landscape

       6.1. Company Market Share Analysis

       6.2. Manufacturers Manufacturing Sites, Area Served, Product

       6.3. Market Competitive Situation and Trends

       6.4. Manufacturers Mergers & Acquisitions, Expansion Plans

7. Market: By Product Segment Analysis

       7.1. Introduction

       7.2. Sales Volume & Revenue Analysis (2021-2030)

       7.3. Therapeutic Agent

              7.3.1. Therapeutic Agent market, 2021 - 2030 (USD Million)

       7.4. Vaccine

               7.4.1. Vaccine market, 2021 - 2030 (USD Million)

       7.5. Genetically Modified Crops

               7.5.1. Genetically Modified Crops market, 2021 - 2030 (USD Million)

       7.6. Speciality Chemicals

               7.6.1. Speciality Chemicals market, 2021 - 2030 (USD Million)

8. Market: By Application Segment Analysis

       8.1. Introduction

       8.2. Sales Volume & Revenue Analysis (2021-2030)

       8.3. Food and Agriculture

              8.3.1.     Food and Agriculture Market, 2021 - 2030 (USD Million)

       8.4. Environment

              8.4.1.     Environment market, 2021 - 2030 (USD Million)

       8.5. Health

              8.5.1.     Health market, 2021 - 2030 (USD Million)

       8.6. Disease Fighting

              8.6.1.     Disease Fighting market, 2021 - 2030 (USD Million)

9. Market: By Component Segment Analysis

       9.1. Introduction

       9.2. Sales Volume & Revenue Analysis (2021-2030)

       9.3. Expression System

              9.3.1.     Expression System market, 2021 - 2030 (USD Million)

       9.4. Cloning Vector

              9.4.1.     Cloning Vector market, 2021 - 2030 (USD Million)

10. Market: By End-User Segment Analysis

       10.1. Introduction

       10.2. Sales Volume & Revenue Analysis (2021-2030)

       10.3. Academic & Government Research Institutes

              10.3.1.   Academic & Government Research Institutes market, 2021 - 2030 (USD Million)

       10.4. Biotechnological and Pharmaceutical Companies

              10.4.1.   Biotechnological and Pharmaceutical Companies market, 2021 - 2030 (USD Million)

       10.5. Others

              10.5.1.   Others Market, 2021 - 2030 (USD Million)

11. Market: Regional Outlook

       11.1 North America

              11.1.1.   North America market, By Product, 2021 - 2030 (USD Million)

              11.1.2.   North America market, By Application, 2021 - 2030 (USD Million)

              11.1.3.   North America market, by End-User, 2021 - 2030 (USD Million)

              11.1.4.   North America market, by Country, 2021 - 2030 (USD Million)

       11.1.4.1. U.S.

                     11.1.4.1.1.   U.S. market, By Product, 2021 - 2030 (USD Million)

                     11.1.4.1.2.   U.S. market, By Application, 2021 - 2030 (USD Million)

                     11.1.4.1.3.   U.S. market, by End-User, 2021 - 2030 (USD Million)

     11.1.4.2.  Canada

                     11.1.4.2.1.   Canada market, By Product, 2021 - 2030 (USD Million)

                     11.1.4.2.2.   Canada market, By Application, 2021 - 2030 (USD Million)

                     11.1.4.2.3.   Canada market, by End-User, 2021 - 2030 (USD Million)

11.2. Europe

              11.2.1.   Europe market, By Product, 2021 - 2030 (USD Million)

              11.2.2.   Europe market, By Application, 2021 - 2030 (USD Million)

              11.2.3.   Europe market, by End-User, 2021 - 2030 (USD Million)

              11.2.4.   Europe market, by country, 2021 - 2030 (USD Million)

    11.2.4.1    U.K.

                     11.2.4.1.1.   U.K. market, By Product, 2021 - 2030 (USD Million)

                     11.2.4.1.2.   U.K. market, By Application, 2021 - 2030 (USD Million)

                     11.2.4.1.3.   U.K. market, by End-User, 2021 - 2030 (USD Million)

   11.2.4.2.           Germany

                     11.2.4.2.1.   Germany market, By Product, 2021 - 2030 (USD Million)

                     11.2.4.2.2.   Germany market, By Application, 2021 - 2030 (USD Million)

                     11.2.4.2.3.   Germany market, by End-User, 2021 - 2030 (USD Million)

   11.2.4.3.           France

                     11.2.4.3.1.   France market, By Product, 2021 - 2030 (USD Million)

                     11.2.4.3.2.   France market, By Application, 2021 - 2030 (USD Million)

                     11.2.4.3.3.   France market, by End-User, 2021 - 2030 (USD Million)

    11.2.4.4.          Rest of Europe

                     11.2.4.4.1.   Rest of Europe market, By Product, 2021 - 2030 (USD Million)

                     11.2.4.4.2.   Rest of Europe market, By Application, 2021 - 2030 (USD Million)

                     11.2.4.4.3.   Rest of Europe market, by End-User, 2021 - 2030 (USD Million)

       11.3.              Asia Pacific

              11.3.1.   Asia Pacific market, By Product, 2021 - 2030 (USD Million)

              11.3.2.   Asia Pacific market, By Application, 2021 - 2030 (USD Million)

              11.3.3.   Asia Pacific market, by End-User, 2021 - 2030 (USD Million)

              11.3.4.   Asia Pacific market, by country, 2021 - 2030 (USD Million)

   11.3.4.1.           China

                     11.3.4.1.1.   China market, By Product, 2021 - 2030 (USD Million)

                     11.3.4.1.2.   China market, By Application, 2021 - 2030 (USD Million)

                     11.3.4.1.3.   China market, by End-User, 2021 - 2030 (USD Million)

   11.3.4.2.           India

                     11.3.4.2.1.   India market, By Product, 2021 - 2030 (USD Million)

                     11.3.4.2.2.   India market, By Application, 2021 - 2030 (USD Million)

                     11.3.4.2.3.   India  market, by End-User, 2021 - 2030 (USD Million)

   11.3.4.3.           Japan

                     11.3.4.3.1.   Japan market, By Product, 2021 - 2030 (USD Million)

                     11.3.4.3.2.   Japan market, By Application, 2021 - 2030 (USD Million)

                     11.3.4.3.3.   Japan market, by End-User, 2021 - 2030 (USD Million)

   11.3.4.4.           South Korea

                     11.3.4.4.1.   South Korea market, By Product, 2021 - 2030 (USD Million)

                     11.3.4.4.2.   South Korea market, By Application, 2021 - 2030 (USD Million)

                     11.3.4.4.3.   South Korea market, by End-User, 2021 - 2030 (USD Million)

11.3.4.5.              Rest of ASIA PACIFIC

                     11.3.4.5.1.   Rest of ASIA PACIFIC market, By Product, 2021 - 2030 (USD Million)

                     11.3.4.5.2.   Rest of ASIA PACIFIC market, By Application, 2021 - 2030 (USD Million)

                     11.3.4.5.3.   Rest of ASIA PACIFIC market, by End-User, 2021 - 2030 (USD Million)

       11.4.              Latin America

              11.4.1.   Latin America market, By Product, 2021 - 2030 (USD Million)

              11.4.2.   Latin America market, By Application, 2021 - 2030 (USD Million)

              11.4.3.   Latin America market, by End-User, 2021 - 2030 (USD Million)

              11.4.4.   Latin America market, by country, 2021 - 2030 (USD Million)

11.4.4.1.              Brazil

                     11.4.4.1.1.   Brazil market, By Product, 2021 - 2030 (USD Million)

                     11.4.4.1.2.   Brazil market, By Application, 2021 - 2030 (USD Million)

                     11.4.4.1.3.   Brazil market, by End-User, 2021 - 2030 (USD Million)

11.4.4.2.              Mexico

                     11.4.4.2.1.   Mexico market, By Product, 2021 - 2030 (USD Million)

                     11.4.4.2.2.   Mexico market, By Application, 2021 - 2030 (USD Million)

                     11.4.4.2.3.   Mexico market, by End-User, 2021 - 2030 (USD Million)

                     11.4.4.3.       Rest of Latin America

                     11.4.4.3.1.   Rest of the Latin America market, By Product, 2021 - 2030 (USD Million)

                     11.4.4.3.2.   Rest of the Latin America market, By Application, 2021 - 2030 (USD Million)

                     11.4.4.3.3.   Rest of the Latin America market, by End-User, 2021 - 2030 (USD Million)

       11.5.              MEA

              11.5.1.   MEA market, By Product, 2021 - 2030 (USD Million)

              11.5.2.   MEA market, By Application, 2021 - 2030 (USD Million)

              11.5.3.   MEA market, by End-User, 2021 - 2030 (USD Million)

              11.5.4.   MEA market, by region, 2021 - 2030 (USD Million)

 

12. Competitive Landscape

       12.1 MONSANTO

              12.1.1.   Company overview

              12.1.2.   Financial performance

              12.1.3.   Product Portfolio Analysis

              12.1.4.   Business Strategy & Recent Development

       12.2. Thermo Fisher Scientific Inc

              12.2.1.   Company overview

              12.2.2.   Financial performance

              12.2.3.   Product Portfolio Analysis

              12.2.4.   Business Strategy & Recent Development

       12.3. Sanofi

              12.3.1.   Company overview

              12.3.2.   Financial performance

              12.3.3.   Product Portfolio Analysis

              12.3.4.   Business Strategy & Recent Development

       12.4. Biogen

              12.4.1.   Company overview

              12.4.2.   Financial performance

              12.4.3.   Product Portfolio Analysis

              12.4.4.   Business Strategy & Recent Development

       12.5. Novartis AG

              12.5.1.   Company overview

              12.5.2.   Financial performance

              12.5.3.   Product Portfolio Analysis

              12.5.4.   Business Strategy & Recent Development

       12.6. Novo Nordisk

              12.6.1.   Company overview

              12.6.2.   Financial performance

              12.6.3.   Product Portfolio Analysis

              12.6.4.   Business Strategy & Recent Development

       12.7. GENSCRIPT

              12.7.1.   Company overview

              12.7.2.   Financial performance

              12.7.3.   Product Portfolio Analysis

              12.7.4.   Business Strategy & Recent Development

       12.8. PFIZER

              12.8.1.   Company overview

              12.8.2.   Financial performance

              12.8.3.   Product Portfolio Analysis

              12.8.4.   Business Strategy & Recent Development

       12.9. BASF

              12.9.1.   Company overview

              12.9.2.   Financial performance

              12.9.3.   Product Portfolio Analysis

              12.9.4.   Business Strategy & Recent Development

        12.10. Bayer

              12.10.1.   Company overview

              12.10.2.   Financial performance

              12.10.3.   Product Portfolio Analysis

              12.10.4.   Business Strategy & Recent Development

        12.11. DuPont Pioneer

              12.11.1.   Company overview

              12.11.2.   Financial performance

              12.11.3.   Product Portfolio Analysis

              12.11.4.   Business Strategy & Recent Development

        12.12. Amgen

              12.12.1.   Company overview

              12.12.2.   Financial performance

              12.12.3.   Product Portfolio Analysis

              12.12.4.   Business Strategy & Recent Development

 

List of Tables (58 Tables)

TABLE 1.  MARKET, By Product, 2021-2030 (USD Million)

TABLE 2.  MARKET FOR Therapeutic Agent, BY REGION, 2021-2030 (USD Million)

TABLE 3.  MARKET FOR Vaccine, BY REGION, 2021-2030 (USD Million)

TABLE 4.  MARKET FOR Genetically Modified Crops, BY REGION, 2021-2030 (USD Million)

TABLE 5.  MARKET FOR Speciality Chemicals, BY REGION, 2021-2030 (USD Million)

TABLE 6. MARKET, By Application, 2021-2030 (USD Million)

TABLE 7. MARKET FOR Food and Agriculture, BY REGION, 2021-2030 (USD Million)

TABLE 8. MARKET FOR Environment, BY REGION, 2021-2030 (USD Million)

TABLE 9. MARKET FOR Health, BY REGION, 2021-2030 (USD Million)

TABLE 10. MARKET FOR Disease Fighting, BY REGION, 2021-2030 (USD Million)

TABLE 11. MARKET, BY END-USER, 2021-2030 (USD Million)

TABLE 12. MARKET FOR Academic & Government Research Institutes, BY REGION, 2021-2030 (USD Million)

TABLE 13. MARKET FOR Biotechnological and Pharmaceutical Companies, BY REGION, 2021-2030 (USD Million)

TABLE 14. MARKET FOR Others, BY REGION, 2021-2030 (USD Million)

TABLE 15. MARKET, By Component, 2021-2030 (USD Million)

TABLE 16. MARKET FOR Expression System, BY REGION, 2021-2030 (USD Million)

TABLE 17. MARKET FOR Cloning Vector, BY REGION, 2021-2030 (USD Million)

TABLE 18. MARKET, BY REGION, 2021-2030 (USD Million)

TABLE 19. NORTH AMERICA MARKET, BY COUNTRY, 2021-2030 (USD Million)

TABLE 20. NORTH AMERICA MARKET, By Product, 2021-2030 (USD Million)

TABLE 21. NORTH AMERICA MARKET, By Application, 2021-2030 (USD Million)

TABLE 22. NORTH AMERICA MARKET, BY END-USER, 2021-2030 (USD Million)

TABLE 23. EUROPE MARKET, BY COUNTRY, 2021-2030 (USD Million)

TABLE 24. EUROPE MARKET, By Product, 2021-2030 (USD Million)

TABLE 25. EUROPE MARKET, By Application, 2021-2030 (USD Million)

TABLE 26. EUROPE MARKET, BY END-USER, 2021-2030 (USD Million)

TABLE 27. ASIA-PACIFIC MARKET, BY COUNTRY, 2021-2030 (USD Million)

TABLE 28. ASIA-PACIFIC MARKET, By Product, 2021-2030 (USD Million)

TABLE 29. ASIA-PACIFIC MARKET, By Application, 2021-2030 (USD Million)

TABLE 30. ASIA-PACIFIC MARKET, BY END-USER, 2021-2030 (USD Million)

TABLE 31. LAMEA MARKET, BY COUNTRY, 2021-2030 (USD Million)

TABLE 32. LAMEA MARKET, By Product, 2021-2030 (USD Million)

TABLE 33. LAMEA MARKET, By Component, 2021-2030 (USD Million)

TABLE 34. LAMEA MARKET, BY END-USER, 2021-2030 (USD Million)

TABLE 35. MONSANTO: COMPANY SNAPSHOT

TABLE 36. MONSANTO: OPERATING SEGMENTS

TABLE 37. Thermo Fisher Scientific Inc: COMPANY SNAPSHOT

TABLE 38. Thermo Fisher Scientific Inc: OPERATING SEGMENTS

TABLE 39. Sanofi: COMPANY SNAPSHOT

TABLE 40. Sanofi: OPERATING SEGMENTS

TABLE 41. Biogen: COMPANY SNAPSHOT

TABLE 42. Biogen: OPERATING SEGMENTS

TABLE 43. Novartis AG: COMPANY SNAPSHOT

TABLE 44. Novartis AG: OPERATING SEGMENTS

TABLE 45. Novo Nordisk: COMPANY SNAPSHOT

TABLE 46. Novo Nordisk: OPERATING SEGMENTS

TABLE 47. GENSCRIPT: COMPANY SNAPSHOT

TABLE 48. GENSCRIPT: OPERATING SEGMENTS

TABLE 49. PFIZER: COMPANY SNAPSHOT

TABLE 50. PFIZER: OPERATING SEGMENTS

TABLE 51. BASF: COMPANY SNAPSHOT

TABLE 52. BASF: OPERATING SEGMENTS

TABLE 53. Bayer: COMPANY SNAPSHOT

TABLE 54. Bayer: OPERATING SEGMENTS

TABLE 55. DuPont Pioneer: COMPANY SNAPSHOT

TABLE 56. DuPont Pioneer: OPERATING SEGMENTS

TABLE 57. Amgen: COMPANY SNAPSHOT

TABLE 58. Amgen: OPERATING SEGMENTS

 

List of Figures (24 Figures)

Figure 1 Market: Research Methodology Steps

Figure 2 Research Design

Figure 3 Breakdown of Primaries: Market

Figure 4 Research Methodology: Hypothesis Building

Figure 5 Market: Product-Based Estimation

Figure 6 Top 12 Companies with Highest No. Of Patent in Last 9 Years

Figure 7 No. Of Patents Granted Per Year, 2019–2021

Figure 8 Import Data for Recombinant DNA Technology, By Country, 2016–2021 (USD Thousand)

Figure 9 Export Data for Recombinant DNA Technology, By Country, 2016–2021 (USD Thousand)

Figure 10 Data Triangulation Methodology

Figure 11 Market, By Application, 2019 vs. 2025 (USD Million)

Figure 12 Market Share, By End-User, 2019 vs. 2025 (USD Million)

Figure 13 Market Share, By Product, 2019 vs. 2025 (USD Million)

Figure 14 Market Share, By Component, 2019 vs. 2025 (USD Million)

Figure 15 Geographical Snapshot of the Market

Figure 16 Therapeutic Agent to Witness Higher CAGR in the Market for Product Segment during the Forecast Period.

Figure 17 Health & disease to Witness Higher CAGR in Market for Application Segment during Forecast Period.

Figure 18 North America Accounted for the Largest Share of the Market, By Regional Basis, in 2019

Figure 19 Market: Drivers, Restraints, Opportunities, and Challenges

Figure 20 North America: Market Snapshot

Figure 21 Asia Pacific: Market Snapshot

Figure 22 Vendor Dive: Evaluation Overview

Choose License Type


$4485
$6449
$8339
Buy Now
"Click to avail the latest sample copy of the report"
Request Sample
"Probe before placing the order"
Pre-Order Enquiry
"Let's optimize your ROI by furnishing the best price"
Request Discount
"Want to curate the report according to your business needs:"
Ask for Customization
Related Reports
    DNA Sequencing Market

     Published Date :Apr-2022


    Breast Cancer Liquid Biopsy Market

     Published Date :Apr-2022


    Digital Biomarkers Market

     Published Date :Jun-2022


Buy Now
Request Sample

Trust Online

  • paypal.png
  • wiretransfers

Follow Us

  • facebook
  • twitter
  • instagram
  • linkedin

Contact Us

  • US: +1-315-636-4233
  • UK: +44-162-237-0614
  • IN: +91-826-083-6500
  • info@strategicmarketresearch.com
  • Strategic Market Research
    26, Broadway Suite 934, New York , 10004

Quick Link

  • Why SMR
  • Research Methodology
  • Media Coverage
  • Join Our Team
  • Press Release
  • Blog

Customer Support

  • FAQs
  • Contact
  • Terms of Use
  • Privacy Policy
  • Disclaimer Policy
  • Return Policy
Copyright © 2022 Strategic Market Research All rights reserved.